Assessment of the (14C) aminopyrine breath test in liver disease.
Different methods of performing the (14C) aminopyrine breath test have been assessed. A tracer dose of 2 muCi without a loading dose and with a single breath collection at two hours was the method selected, since it gave the best discrimination between patients with hepatocellular diseases and normal subjects (5.2 +/- 0.2%, mean +/- SEM). Reduced values occurred in patients with chronic active hepatitis (with and without cirrhosis) (1.5 +/- 0.2%), alcoholic cirrhosis (1.7 +/- 0.4%) and hepatitis (2.5 +/- 0.3%), and late primary biliary cirrhosis suggesting defective microsomal function with respect to demethylation. Normal results were common in early primary biliary cirrhosis. Two weeks of prednisolone therapy caused some improvement in the breath test in nine of 10 patients with chronic active hepatitis. It is concluded that the (14C) aminopyrine breath test is a simple test for detecting hepatocellular dysfunction, but has no obvious diagnostic advantage over the determination of serum aspartate transaminase and two hour post-prandial bile-acids.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000632:Aminopyrine; D001379:Azathioprine / Q000627:therapeutic use; D001944:Breath Tests / Q000379:methods*; D002250:Carbon Radioisotopes; D002908:Chronic Disease; D005260:Female; D006505:Hepatitis / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D008103:Liver Cirrhosis / Q000175:diagnosis; D008107:Liver Diseases / Q000175:diagnosis*; D008111:Liver Function Tests / Q000379:methods; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D013997:Time Factors
D002250:Carbon Radioisotopes; D000632:Aminopyrine; D011239:Prednisolone; D001379:Azathioprine